Medtronic plcNYSE: MDT

No material news in the last 48 hours.

No material news in the last 48 hours.

On May 20, 2026, Medtronic announced it will acquire SPR Therapeutics for approximately $650 million in cash, expected to close in H1 of fiscal 2027, strengthening its peripheral nerve stimulation (PNS) and chronic pain franchise. The deal lands amid heavy stock pressure (MDT down ~21% YTD, trading near $77.64) and a broader restructuring that consolidates aortic, cardiac surgery, structural heart, coronary and renal denervation into two new business units. Investors are weighing whether SPR is enough to revive growth optics versus reinforcing perceptions of bolt-on M&A as patchwork. A dividend increase (47th consecutive year) is also expected this month. Risks: integration execution, restructuring disruption, and ongoing portfolio reshaping including the MiniMed spinoff.

Medtronic announces intent to acquire SPR Therapeutics, Inc.news.medtronic.comMedtronic (MDT) Stock: Shares Dip Amid $650M SPR Therapeutics Acquisitioncoincentral.comMedtronic to acquire peripheral nerve stim developer SPR Therapeuticsmassdevice.com

On May 7, 2026, Medtronic informed its 370 Santa Rosa-based employees it would exit the area over two years, relocating operations to Santa Ana, Minnesota and Galway, Ireland — ending nearly three decades of local presence. The closure accompanies a broader restructuring: Medtronic is combining its aortic and cardiac surgery businesses into a new cardiovascular surgery division and merging structural heart, coronary, and renal denervation into a new interventional cardiology therapies unit. The MiniMed diabetes business spinoff filed for IPO and has already triggered 80+ California layoffs. A False Claims Act case alleging kickback-tainted device claims was resolved via joint stipulation of dismissal, providing some legal overhang relief. Fiscal Q4 results are scheduled for May 20, 2026. Shares are down ~21% YTD at ~$77, but Wall Street has a Strong Buy consensus and $110 median target.

Medtronic leaving Santa Rosa after nearly three decades, more than 300 jobs affectedpressdemocrat.comMedtronic restructures its heart and circulation business as stock pressure mountsstartribune.comMedtronic's diabetes spinoff MiniMed files for IPOmedtechdive.com

A May 17 report deepened concerns over Medtronic's North Bay California manufacturing exit, with the company moving its Santa Rosa operations (370 employees) to Minnesota and Galway, Ireland by spring 2028, part of a broader restructuring that also consolidates its cardiovascular surgery and interventional cardiology businesses. The news lands two days before Medtronic's scheduled fiscal Q4 results on May 20, 2026, raising the stakes for management's commentary on cost-out execution and the planned MiniMed diabetes spinoff, which has already filed for IPO. Shares are down 11.6% over the past month and 20.7% YTD to $76.97, even as a DCF analysis flags 20.6% undervaluation and the median analyst PT sits at $111. The risk: restructuring charges and execution slippage on the diabetes separation could overshadow growth from the Catheter Ablation System and Hugo Robotic Surgical platform, prolonging the stock's underperformance.

Medtronic exit deepens questions about North Bay's manufacturing futurepressdemocrat.comMedtronic restructures its heart and circulation business as stock pressure mountsstartribune.comIs It Time To Revisit Medtronic (MDT) After Its Recent Share Price Slump?simplywall.st

MDT shares climbed 3.3% on May 12 to ~$77 ahead of the May 20 fiscal Q4 2026 earnings release, with traders citing dismissal of a long-running legal matter that reduced headline risk and recent cardiac rhythm management clinical/regulatory updates building 'pipeline momentum.' Strategic activity continues: Medtronic announced on May 7 it will close its Santa Rosa, CA facility (370 jobs) by spring 2028, relocating to Minnesota and Galway as part of broader restructuring. The company also combined its aortic/cardiac surgery and structural heart/coronary/renal denervation units (>$12B annual sales) under new cardiovascular divisions. The MiniMed diabetes spinoff filed for IPO. Bear case: restructuring execution risk, layoff-related charges, slow stock performance despite operational fixes, and the diabetes spinout introduces transition uncertainty; median PT of $111 implies upside but consensus is muted.

Medtronic shares climb as investors digest legal overhang relief and fresh cardiac-tech updatesquiverquant.comMedical device maker Medtronic leaving Santa Rosa after nearly three decadespressdemocrat.comMedtronic restructures its heart and circulation business as stock pressure mountsstartribune.com

Medtronic stock gained 3.3% on May 12, 2026 ahead of its May 20 earnings report, with traders pointing to dismissal of a long-running legal overhang reducing perceived headline risk. The company informed its 370 Santa Rosa employees on May 7 it will exit the site by 2028, relocating operations to Santa Ana, Minnesota and Galway, Ireland. Medtronic is consolidating its $12B+ cardiovascular business into a new cardiovascular surgery division and a new interventional cardiology therapies group. Diabetes spinoff MiniMed filed for IPO, and IR leadership shifts are underway. Median analyst price target is $97.50, suggesting upside from current ~$77.

Medical device maker Medtronic leaving Santa Rosa after nearly three decadespressdemocrat.comMedtronic shares climb on legal overhang relief and cardiac-tech updatesquiverquant.comMedtronic restructures its heart and circulation businessstartribune.com

Medtronic announced on May 7, 2026 that it will close its Santa Rosa, California facility, ending nearly three decades of local operations and affecting roughly 370 employees, with departures starting spring 2027 and full closure spring 2028. Operations will relocate to Santa Ana, Minnesota and Galway, Ireland. In parallel, Medtronic combined its Cardiac Surgery and Aortic units into a new Cardiovascular Surgery business led by Karim Bandali, and merged structural heart, coronary, and renal denervation businesses into a new interventional cardiology therapies unit. The stock traded at $82.35 on May 13, down ~12% over the past month and ~24% over three months, as investors brace for the fiscal Q4 report on June 3. Bear case: restructuring signals weaker-than-hoped growth in the heart franchise; shares remain 40% below 2021 highs.

Medtronic merges Cardiac Surgery, Aortic unitsmassdevice.comMedical device maker Medtronic leaving Santa Rosapressdemocrat.comMedtronic restructures its heart and circulation businessstartribune.com

On May 7, Medtronic notified roughly 370 Santa Rosa-based employees that it will exit the Northern California site by 2028, relocating operations primarily to Santa Ana, Minnesota and Galway, Ireland. The closure follows a broader restructuring that merged Cardiac Surgery and Aortic into a new Cardiovascular Surgery unit under Karim Bandali and combined structural heart, coronary and renal denervation into a new interventional cardiology therapies business (>$12B in annual sales). Medtronic will report fiscal Q4 and full-year results on June 3. Shares traded $74.60-$77.13 on May 12, near 52-week lows, down ~40% from the 2021 peak. Risk: portfolio simplification execution; consensus is still Buy with a $107.80 average target.

Medtronic leaving Santa Rosa after nearly three decades, more than 300 jobs affectedpressdemocrat.comMedtronic merges Cardiac Surgery, Aortic units into Cardiovascular Surgery businessmassdevice.comMedtronic restructures its heart and circulation business as stock pressure mountsstartribune.com

On May 7, Medtronic informed its 370 Santa Rosa, California-based employees that it plans to leave the area within two years, ending nearly three decades of operations. Santa Rosa work will relocate primarily to Santa Ana, Minnesota and Galway, Ireland, with completion targeted for spring 2028. The closure is part of a broader cardiovascular restructuring that combines the aortic and cardiac surgery businesses into a new cardiovascular surgery division and merges structural heart, coronary, and renal denervation businesses into a new interventional cardiology therapies business. The combined heart and circulation division generates more than $12B in annual sales. Medtronic also released positive ALERT Trial data presented at ACC and published in JACC, showing AI-enabled clinician notifications significantly improve evaluation and intervention rates for aortic stenosis and mitral regurgitation patients. The MiniMed diabetes spinoff filed for IPO. MDT trades at $75.86 (May 11), down 2.2% week, 10.1% month, and 19.2% YTD. 19-analyst consensus remains Buy with average target $108.21. Risk: restructuring execution risk amid weak share performance.

Medical device maker Medtronic leaving Santa Rosa after nearly three decadespressdemocrat.comMedtronic restructures its heart and circulation business as stock pressure mountsstartribune.comMedtronic Study Reveals AI-Enabled Clinician Alerts Significantly Improve Evaluation and Valve Interventioninvestingnews.com

Medtronic told its 370 Santa Rosa employees on May 7, 2026 it will exit the area by 2028, relocating operations primarily to Santa Ana, Minnesota and Galway, Ireland. On May 6, the company merged its Cardiac Surgery and Aortic units into a new Cardiovascular Surgery business led by Karim Bandali, and combined structural heart, coronary, and renal denervation businesses into a new interventional cardiology therapies unit. The restructuring comes as the stock trades ~27% below its 52-week high of $106.33 amid persistent share-price pressure. Q4/full-year fiscal results are scheduled for June 3. Risk is execution disruption during the reorganization, while analysts maintain a Buy consensus with average target ~$108.

Medical device maker Medtronic leaving Santa Rosapressdemocrat.comMedtronic merges Cardiac Surgery, Aortic units into Cardiovascular Surgery businessmassdevice.comMedtronic restructures its heart and circulation business as stock pressure mountsstartribune.com

Medtronic announced major restructuring merging Cardiac Surgery and Aortic units into Cardiovascular Surgery business, combining structural heart, coronary, renal denervation into interventional cardiology therapies division. Company plans to exit Santa Rosa CA facility by 2028 (370 employees). April 24 data breach confirmed affecting nearly 9M records. Company received CE Mark for Stealth AXiS system and launched Adaptive Deep Brain Stimulation in India. Stock at $78.50 on May 7, down 27% from 52-week high of $106.33, down 19.2% YTD. JP Morgan analyst Robbie Marcus maintains Hold, lowered PT from $105 to $100. Q4 FY2026 earnings due June 3.

Medical device maker Medtronic leaving Santa Rosa after nearly three decadespressdemocrat.comMedtronic merges Cardiac Surgery, Aortic units into Cardiovascular Surgery businessmassdevice.comPRIVACY ALERT: Medtronic Under Investigation for Data Breachprnewswire.com

Medtronic received CE mark approval on April 28 for Stealth AXiS surgical system for spine/cranial procedures, enabling European market expansion. Company disclosed unauthorized access to corporate IT systems on April 24 via 8-K filing, though products and patient operations unaffected. Named to TIME100 Companies list for Hugo robotic-assisted surgery system cleared by FDA in December 2025. Presented positive Affera cardiac arrhythmia data at HRS Annual Meeting in late April. Jefferies lowered price target from $108 to $95 on April 23 citing analyst concerns. Q4 FY2026 and full-year results scheduled for June 3, 2026. 21 analysts rate Buy with $108.21 target.

Medtronic Press Releasesnews.medtronic.comInsider Monkey - Stealth AXiS Approvalinsidermonkey.comYahoo Finance - MDT Newsfinance.yahoo.com